STTK
Shattuck Labs, Inc. NASDAQ Listed Oct 9, 2020$6.68
After hrs
$6.70
+0.30%
Mkt Cap $320.0M
52w Low $0.71
78.3% of range
52w High $8.33
50d MA $6.32
200d MA $3.41
P/E (TTM)
-10.0x
EV/EBITDA
-4.2x
P/B
5.9x
Debt/Equity
0.0x
ROE
-59.2%
P/FCF
-6.4x
RSI (14)
—
ATR (14)
—
Beta
1.29
50d MA
$6.32
200d MA
$3.41
Avg Volume
539.7K
About
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced s…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | BMO | -0.12 | -0.12 | +0.0% | 4.73 | -3.6% | +7.8% | +26.6% | +27.3% | +26.0% | +24.3% | — |
| Nov 6, 2025 | BMO | -0.15 | -0.14 | +6.7% | 2.04 | -2.0% | -3.9% | -2.9% | -7.4% | -2.9% | -5.9% | — |
| Aug 14, 2025 | BMO | -0.25 | -0.24 | +4.0% | 0.81 | -1.3% | +6.1% | +23.4% | +25.8% | +27.1% | +24.6% | — |
| May 1, 2025 | BMO | -0.29 | -0.27 | +6.9% | 0.99 | +0.0% | +9.2% | +0.7% | +1.0% | -12.0% | -11.8% | — |
| Mar 27, 2025 | BMO | -0.38 | -0.37 | +2.6% | 1.18 | -2.5% | -3.4% | -10.2% | -19.5% | -28.3% | -16.6% | — |
| Nov 14, 2024 | BMO | -0.41 | -0.33 | +19.5% | 1.22 | +2.5% | +12.3% | +1.6% | -9.0% | -6.6% | -9.0% | — |
| Aug 1, 2024 | BMO | -0.41 | -0.42 | -2.4% | 3.98 | -0.5% | -5.3% | -8.3% | -23.1% | -22.4% | -24.1% | — |
| May 2, 2024 | BMO | -0.47 | -0.37 | +21.3% | 10.86 | +1.8% | +2.2% | -0.7% | +2.9% | -1.0% | -3.4% | — |
| Feb 29, 2024 | BMO | -0.51 | -0.41 | +19.6% | 8.99 | -1.0% | -2.9% | +7.3% | +5.3% | +6.3% | +5.3% | — |
| Nov 9, 2023 | BMO | -0.52 | -0.65 | -25.0% | 2.37 | -5.5% | -23.2% | -22.4% | -20.3% | -12.2% | -8.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Cantor Fitzgerald | Initiates | Overweight | — | $7.74 | $7.90 | +2.1% | -0.3% | -2.7% | -8.4% | -7.6% | -9.7% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.53 | $7.62 | +1.2% | +4.6% | +3.1% | +2.9% | +1.6% | +2.8% |
| Mar 13 | Citigroup | Maintains | Neutral → Neutral | — | $6.13 | $6.21 | +1.3% | -2.3% | -1.8% | -2.9% | -1.5% | -0.5% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $5.10 | $5.27 | +3.3% | +17.5% | +18.0% | +16.9% | +15.3% | +20.2% |
| Jan 6 | Citigroup | Maintains | Neutral → Neutral | — | $3.89 | $3.96 | +1.8% | +2.3% | +23.4% | +19.3% | +22.1% | +18.0% |
| Dec 1 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.10 | $2.25 | +7.1% | +14.8% | +18.1% | +23.8% | +41.4% | +47.6% |
| Aug 14 | Needham | Maintains | Hold → Hold | — | $0.81 | $0.80 | -1.3% | +6.1% | +23.4% | +25.8% | +27.1% | +24.6% |
| Aug 14 | Leerink Partners | Maintains | Outperform → Outperform | — | $0.81 | $0.80 | -1.3% | +6.1% | +23.4% | +25.8% | +27.1% | +24.6% |
| Mar 27 | Needham | Maintains | Hold → Hold | — | $1.18 | $1.15 | -2.5% | -3.4% | -10.2% | -19.5% | -28.3% | -16.6% |
| Mar 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.18 | $1.15 | -2.5% | -3.4% | -10.2% | -19.5% | -28.3% | -16.6% |
Recent Filings
8-K
Shattuck Labs, Inc. -- 8-K Filing
Shattuck Labs (STTK) expects Phase 1 SL-325 data in Q2 2026 and plans Phase 2 initiation for Crohn's disease in Q3 2026, representing pipeline advancement for the clinical-stage biotech.
Mar 5
8-K
Shattuck Labs, Inc. -- 8-K Filing
Shattuck Labs shareholders must submit shareholder proposals by February 27, 2026 for inclusion in the 2026 proxy statement.
Feb 5
Data updated apr 27, 2026 3:24am
· Source: massive.com